Treatment Approaches for Myeloproliferative Neoplasms

This segment discusses the current classification of myeloproliferative neoplasms (MPNs) and the pathogenesis of these disorders, particularly the role of the JAK-STAT signaling pathway. It also presents a treatment algorithm for higher-risk myelofibrosis, with a focus on the use of JAK inhibitors such as ruxolitinib, fedratinib, pacritinib, and momelotinib.

Now Viewing

EP: 1.Treatment Approaches for Myeloproliferative Neoplasms

EP: 2.Patient Case 1: Patient with Intermediate Risk Myelofibrosis

EP: 3.Review of COMFORT I and COMFORT II Trials

EP: 4.Expert Takeaways from COMFORT I and II Trial Results

Related Videos